These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 18645266)

  • 1. Growth hormone inhibitors in prostate cancer: a systematic analysis.
    Schmid HP; Gregorin J; Altwein JE
    Urol Int; 2008; 81(1):17-22. PubMed ID: 18645266
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Luteinizing hormone-releasing hormone agonists in the treatment of prostate cancer: a review of their discovery, development, and place in therapy.
    Moreau JP; Delavault P; Blumberg J
    Clin Ther; 2006 Oct; 28(10):1485-508. PubMed ID: 17157109
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Degarelix: a new approach for the treatment of prostate cancer.
    Persson BE; Kold Olesen T; Jensen JK
    Neuroendocrinology; 2009; 90(3):235-44. PubMed ID: 19602868
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Secondary hormonal therapy for advanced prostate cancer.
    Lam JS; Leppert JT; Vemulapalli SN; Shvarts O; Belldegrun AS
    J Urol; 2006 Jan; 175(1):27-34. PubMed ID: 16406864
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of luteinizing hormone-releasing hormone therapy in locally advanced prostate cancer and biochemical failure: considerations for optimal use.
    Teillac P; Bono AV; Irani J; Wirth MP; Zlotta AR
    Clin Ther; 2005 Mar; 27(3):273-85. PubMed ID: 15878381
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New treatment approaches for prostate cancer based on peptide analogues.
    Stangelberger A; Schally AV; Djavan B
    Eur Urol; 2008 May; 53(5):890-900. PubMed ID: 18201818
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A combination therapy of dexamethasone and somatostatin analog reintroduces objective clinical responses to LHRH analog in androgen ablation-refractory prostate cancer patients.
    Koutsilieris M; Mitsiades C; Dimopoulos T; Ioannidis A; Ntounis A; Lambou T
    J Clin Endocrinol Metab; 2001 Dec; 86(12):5729-36. PubMed ID: 11739429
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gonadotropin-releasing hormone agonists reduce the migratory and the invasive behavior of androgen-independent prostate cancer cells by interfering with the activity of IGF-I.
    Montagnani Marelli M; Moretti RM; Mai S; Procacci P; Limonta P
    Int J Oncol; 2007 Jan; 30(1):261-71. PubMed ID: 17143537
    [TBL] [Abstract][Full Text] [Related]  

  • 9. GnRH receptor and androgen receptor status and outcome of advanced prostate carcinomas.
    Szabó J; Bartók K; Krenács T; Szepesváry Z; Szende B
    Anticancer Res; 2009 Feb; 29(2):681-4. PubMed ID: 19331222
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination of somatostatin analogues and dexamethasone (anti-survival-factor concept) with luteinizing hormone-releasing hormone in androgen ablation-refractory prostate cancer with bone metastasis.
    Koutsilieris M; Dimopoulos T; Milathianakis C; Bogdanos J; Karamanolakis D; Pissimissis N; Halapas A; Lembessis P; Papaioannou A; Sourla A
    BJU Int; 2007 Jul; 100 Suppl 2():60-2. PubMed ID: 17594363
    [No Abstract]   [Full Text] [Related]  

  • 11. Genetic variation in the SST gene and its receptors in relation to circulating levels of insulin-like growth factor-I, IGFBP3, and prostate cancer risk.
    Johansson M; McKay JD; Wiklund F; Rinaldi S; Hallmans G; Bälter K; Adami HO; Grönberg H; Stattin P; Kaaks R
    Cancer Epidemiol Biomarkers Prev; 2009 May; 18(5):1644-50. PubMed ID: 19423539
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer.
    Klotz L; Boccon-Gibod L; Shore ND; Andreou C; Persson BE; Cantor P; Jensen JK; Olesen TK; Schröder FH
    BJU Int; 2008 Dec; 102(11):1531-8. PubMed ID: 19035858
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The neuroendocrine phenotype in prostate cancer: basic and clinical aspects.
    Mosca A; Berruti A; Russo L; Torta M; Dogliotti L
    J Endocrinol Invest; 2005; 28(11 Suppl International):141-5. PubMed ID: 16625864
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gonadotropin-releasing hormone in apoptosis of prostate cancer cells.
    Kraus S; Naor Z; Seger R
    Cancer Lett; 2006 Mar; 234(2):109-23. PubMed ID: 16546667
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapy of experimental hepatic cancers with cytotoxic peptide analogs targeted to receptors for luteinizing hormone-releasing hormone, somatostatin or bombesin.
    Szepeshazi K; Schally AV; Treszl A; Seitz S; Halmos G
    Anticancer Drugs; 2008 Apr; 19(4):349-58. PubMed ID: 18454045
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intermittent androgen deprivation for locally advanced and metastatic prostate cancer: results from a randomised phase 3 study of the South European Uroncological Group.
    Calais da Silva FE; Bono AV; Whelan P; Brausi M; Marques Queimadelos A; Martin JA; Kirkali Z; Calais da Silva FM; Robertson C
    Eur Urol; 2009 Jun; 55(6):1269-77. PubMed ID: 19249153
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment options for androgen-independent prostate cancer.
    Gulley J; Figg WD; Dahut WL
    Clin Adv Hematol Oncol; 2003 Jan; 1(1):49-57. PubMed ID: 16227960
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Undetectable level of prostate specific antigen (PSA) nadir predicts PSA biochemical failure in local prostate cancer with delayed-combined androgen blockade.
    Soga N; Arima K; Sugimura Y
    Jpn J Clin Oncol; 2008 Sep; 38(9):617-22. PubMed ID: 18697759
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting of cytotoxic luteinizing hormone-releasing hormone analogs to breast, ovarian, endometrial, and prostate cancers.
    Nagy A; Schally AV
    Biol Reprod; 2005 Nov; 73(5):851-9. PubMed ID: 16033997
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Degarelix for prostate cancer.
    Doehn C; Sommerauer M; Jocham D
    Expert Opin Investig Drugs; 2009 Jun; 18(6):851-60. PubMed ID: 19453267
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.